INGEVITY CORP (NGVT)

Sector: Materials

    Home/Companies/NGVT/Annual Meeting

2026 Annual Meeting Analysis

INGEVITY CORP · Meeting: April 29, 2026

Policy v1.2medium confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

9

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors

9 FOR
✓ FOR
Luis Fernandez-Moreno

Director since 2016 with deep specialty chemicals industry experience; the 3-year TSR trigger does not apply because NGVT outperformed the disclosed peer group median by +5.9 percentage points over three years; no overboarding, attendance, or independence concerns.

✓ FOR
Diane H. Gulyas

Director since 2019 with extensive chemicals and global manufacturing experience; NGVT outperformed the peer group median over three years so the TSR trigger does not apply; holds one outside public board seat (Expeditors International), well within the four-board limit.

✓ FOR
Bruce D. Hoechner

Director since 2023 and independent Board Chair; joined within the last three years during an already-challenged period, and NGVT has since outperformed peer median; holds one outside public board seat (Curtiss-Wright), no overboarding concern.

✓ FOR
David H. Li

Appointed to the board in April 2025 — well within the 24-month new-director exemption from the TSR trigger; serves as President and CEO with relevant specialty materials background; holds one outside public board seat (Hexcel), compliant with the policy's two-board limit for sitting CEOs.

✓ FOR
Frederick J. Lynch

Director since 2016 with strong manufacturing and CEO-level experience; NGVT's 3-year TSR of -2.7% outperforms the peer group median of -8.6% by +5.9 percentage points, so the TSR trigger does not apply; no public company board seats beyond Ingevity, no overboarding concern.

✓ FOR
Karen G. Narwold

Director since 2019 with legal, governance, and sustainability expertise relevant to Ingevity's operations; NGVT outperformed the peer group median over three years so the TSR trigger does not apply; holds two outside public board seats (Standard Lithium, Calumet), within the four-board limit.

✓ FOR
F. David Segal

Appointed in April 2025 — well within the 24-month new-director exemption from the TSR trigger; brings capital allocation and investment expertise; no outside public company board seats.

✓ FOR
J. Kevin Willis

Director since 2024 — within the 24-month new-director exemption from the TSR trigger; current CFO of Valvoline with deep financial expertise and designated audit committee financial expert; no outside public company board seats beyond Ingevity.

✓ FOR
Benjamin G. (Shon) Wright

Director since 2022 with global operations and industrial manufacturing experience; NGVT outperformed the peer group median over three years so the TSR trigger does not apply; no outside public company board seats, no overboarding concern.

All nine director nominees receive a FOR vote. The primary TSR concern — Ingevity's negative 3-year stock return — is mitigated by the fact that NGVT outperformed its disclosed compensation peer group median by approximately +6 percentage points over three years, so the named-peer TSR trigger does not fire for any director. Four of the nine nominees joined within the last 24 months and are exempt from the TSR test under policy. The board has meaningful refreshment, strong relevant skills, disclosed a board skills matrix, appropriate audit committee financial expertise, and no overboarding violations.

Say on Pay

✓ FOR

CEO

David H. Li

Total Comp

$12,839,719

Prior Support

91%%

The 2025 say-on-pay vote received 91% support, indicating broad shareholder endorsement of the compensation program. The pay structure is heavily weighted toward variable, performance-linked pay — the CEO's target pay mix shows base salary representing only about 16% of total direct compensation, well below the 40% fixed-pay threshold that would trigger a concern, with the remaining 84% in at-risk annual incentive and long-term equity awards. The long-term equity program uses relative total shareholder return and EBITDA growth metrics over a three-year period, which are meaningful performance conditions; the 2023 performance stock awards paid out at only 24% of target due to missed earnings and return-on-capital targets, demonstrating that the plan genuinely withholds pay when performance falls short, consistent with the policy's pay-for-performance alignment requirement.

Auditor Ratification

✓ FOR

Auditor

PricewaterhouseCoopers LLP

Tenure

N/A

Audit Fees

N/A

Non-Audit Fees

N/A

tenure not disclosed

PwC is a Big 4 firm appropriate for a $2.4 billion public company. The proxy does not disclose PwC's exact tenure or the specific fee breakdown in the text provided, so the tenure trigger and non-audit fee ratio test cannot be applied; per policy, a FOR vote is the default when tenure is not confirmed, and the absence of fee data is noted as a minor gap rather than a disqualifying factor. No material financial restatements are mentioned.

Overall Assessment

The 2026 Ingevity annual meeting presents a clean ballot with no significant governance red flags: all nine director nominees receive a FOR vote because NGVT outperformed its peer group median over the past three years despite a modestly negative absolute return, and four new directors are exempt from TSR scrutiny under the 24-month new-director rule. The say-on-pay program earns support based on strong prior-year shareholder approval (91%), a pay mix that is overwhelmingly performance-based, and demonstrated willingness to reduce payouts when financial targets are missed.

Filing date: March 17, 2026·Policy v1.2·medium confidence

Compensation Peer Group

37 companies disclosed in 2026 proxy filing

ASIXAdvanSix Inc.
ATECAlphatec Holdings, Inc.
ANGOAngioDynamics, Inc.
ANIKAnika Therapeutics, Inc.
AORTArtivion, Inc.
ASHAshland Inc.
ATRCAtriCure, Inc.
AVNSAvanos Medical, Inc.
AVNTAvient Corp.
BCPCBalchem Corp.
BVSBioventus Inc.
CBTCabot Corp.
CNMDCONMED Corporation
CUTRCutera, Inc.
ECVTEcovyst Inc.
ESIElement Solutions Inc
FULH.B. Fuller Co.
HXLHexcel Corp.
IOSPInnospec Inc.
IARTIntegra LifeSciences Holdings Corporation
KOPKoppers Holdings Inc.
LMATLeMaitre Vascular, Inc.
MATVMativ Holdings, Inc.
MDXGMiMedx Group, Inc.
MTXMinerals Technologies Inc.
NUVANuVasive, Inc.
OSUROraSure Technologies, Inc.
OECOrion S.A.
OFIXOrthofix Medical Inc.
PCRXPacira BioSciences, Inc.
KWRQuaker Chemical Corp.
SXTSensient Technologies Corp.
SCLStepan Co.
TROXTronox Holdings
VNDAVanda Pharmaceuticals Inc.
Verical Corporation
ZIMVZimVie Inc.